Clinical Trial Update: Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE [Phase 3]

View source ↗

Summary

Phase 3 trial results for dabigatran etexilate in the long-term prevention of recurrent symptomatic venous thromboembolism have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Pradaxa (dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Venous Thromboembolism | Phase 3 | Status: COMPLETED | Results posted: 2012-03-02